International Stem Cell (ISCO) Upgraded to “Buy” by Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of International Stem Cell (OTCMKTS:ISCO) from a hold rating to a buy rating in a research report report published on Friday. They currently have $1.75 price target on the biotechnology company’s stock.

According to Zacks, “International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. “

OTCMKTS ISCO opened at $1.60 on Friday. The stock has a market capitalization of $10.66 million, a price-to-earnings ratio of -1.09 and a beta of -0.24. International Stem Cell has a 1-year low of $1.25 and a 1-year high of $1.77.

International Stem Cell (OTCMKTS:ISCO) last released its earnings results on Thursday, November 15th. The biotechnology company reported ($0.10) earnings per share for the quarter. The firm had revenue of $3.20 million during the quarter. International Stem Cell had a negative net margin of 23.26% and a negative return on equity of 123.16%. Equities research analysts anticipate that International Stem Cell will post -0.32 earnings per share for the current year.

About International Stem Cell

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

Featured Article: Purposes and Functions of the Federal Reserve

Get a free copy of the Zacks research report on International Stem Cell (ISCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.